Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Inclusion body myositis: therapeutic approaches.

Aggarwal, Rohit and Oddis, Chester V (2012) Inclusion body myositis: therapeutic approaches. Degener Neurol Neuromuscul Dis, 2. 43 - 52.

Available under License : See the attached license file.

Download (180kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


The idiopathic inflammatory myopathies are a heterogeneous group of diseases that include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and other less common myopathies. These are clinically and histopathologically distinct diseases with many shared clinical features. IBM, the most commonly acquired inflammatory muscle disease occurs in individuals aged over 50 years, and is characterized by slowly progressive muscle weakness and atrophy affecting proximal and distal muscle groups, often asymmetrically. Unlike DM and PM, IBM is typically refractory to immunotherapy. Although corticosteroids have not been tested in randomized controlled trials, the general consensus is that they are not efficacious. There is some suggestion that intravenous immunoglobulin slows disease progression, but its long-term effectiveness is unclear. The evidence for other immunosuppressive therapies has been derived mainly from case reports and open studies and the results are discouraging. Only a few clinical trials have been conducted on IBM, making it difficult to provide clear recommendations for treatment. Moreover, IBM is a slowly progressive disease so assessment of treatment efficacy is problematic due to the longer-duration trials needed to determine treatment effects. Newer therapies may be promising, but further investigation to document efficacy would be expensive given the aforementioned need for longer trials. In this review, various treatments that have been employed in IBM will be discussed even though none of the interventions has sufficient evidence to support its routine use.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Aggarwal, Rohitroa19@pitt.eduROA19
Oddis, Chester Vcvo5@pitt.eduCVO5
Date: 2012
Date Type: Publication
Journal or Publication Title: Degener Neurol Neuromuscul Dis
Volume: 2
Page Range: 43 - 52
DOI or Unique Handle: 10.2147/dnnd.s19899
Schools and Programs: School of Medicine > Medicine
Refereed: Yes
Uncontrolled Keywords: clinical features, inclusion body myositis, treatment
Date Deposited: 03 Dec 2012 22:13
Last Modified: 03 Apr 2019 15:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item